Global Overactive Bladder Treatment Market

1 INTRODUCTION OF GLOBAL OVERACTIVE BLADDER TREATMENTMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL OVERACTIVE BLADDER TREATMENTMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE
5.1 Idiopathic Overactive Bladder
5.2 Neurogenic Overactive Bladder
5.2.1 Overactive Bladder in Parkinson's Disease
5.2.2 Overactive Bladder in Stroke
5.2.3 Overactive Bladder in Multiple Sclerosis
5.2.4 Overactive Bladder in Spinal Cord Injury
5.2.5 Overactive Bladder in Other Disorders

6 GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY PHARMACOTHERAPY
6.1 Anticholinergics
6.1.1 Solifenacin
6.1.2 Oxybutynin
6.1.3 Fesoterodine
6.1.4 Darifenacin
6.1.5 Tolterodine
6.1.6 Trospium
6.1.7 Other Anticholinergics
6.2 Mirabegron
6.3 Botox
6.4 Neurostimulation
6.5 Intravesical Instillation

7 GLOBAL OVERACTIVE BLADDER TREATMENTMARKET, BY GEOGRAPHY
7.1 Overview
7.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Rest of Europe
7.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of Asia Pacific
7.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
7.5.1 Brazil
7.5.2 Argentina
7.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

8 GLOBAL OVERACTIVE BLADDER TREATMENTMARKETCOMPETITIVE LANDSCAPE
8.1 Overview
8.2 Company Market Share
8.3 Vendor Landscape
8.4 Key Development Strategies

9 COMPANY PROFILES
9.1 Astellas Pharma Inc.
9.1.1 Overview
9.1.2 Financial Performance
9.1.3 Product Outlook
9.1.4 Key Developments

9.2 Pfizer, Inc.
9.2.1 Overview
9.2.2 Financial Performance
9.2.3 Product Outlook
9.2.4 Key Developments

9.3 Teva Pharmaceutical Industries Limited
9.3.1 Overview
9.3.2 Financial Performance
9.3.3 Product Outlook
9.3.4 Key Developments

9.4 Allergan, PLC.
9.4.1 Overview
9.4.2 Financial Performance
9.4.3 Product Outlook
9.4.4 Key Developments

9.5 Mylan N.V.
9.5.1 Overview
9.5.2 Financial Performance
9.5.3 Product Outlook
9.5.4 Key Developments

9.6 Endo International PLC
9.6.1 Overview
9.6.2 Financial Performance
9.6.3 Product Outlook
9.6.4 Key Developments

9.7 Hisamitsu Pharmaceutical Co., Inc.
9.7.1 Overview
9.7.2 Financial Performance
9.7.3 Product Outlook
9.7.4 Key Developments

9.8 Sanofi
9.8.1 Overview
9.8.2 Financial Performance
9.8.3 Product Outlook
9.8.4 Key Developments

9.9 Aurobindo Pharma Limited
9.9.1 Overview
9.9.2 Financial Performance
9.9.3 Product Outlook
9.9.4 Key Development

9.10 Johnson & Johnson
9.10.1 Overview
9.10.2 Financial Performance
9.10.3 Product Outlook
9.10.4 Key Development

9.11 Intas Pharmaceuticals Ltd.
9.11.1 Overview
9.11.2 Financial Performance
9.11.3 Product Outlook
9.11.4 Key Development

9.12 Apotex Inc.
9.12.1 Overview
9.12.2 Financial Performance
9.12.3 Product Outlook
9.12.4 Key Development

9.13 Macleods Pharmaceuticals Ltd.
9.13.1 Overview
9.13.2 Financial Performance
9.13.3 Product Outlook
9.13.4 Key Development

9.14 Medtronic PLC
9.14.1 Overview
9.14.2 Financial Performance
9.14.3 Product Outlook
9.14.4 Key Development

9.15 Cogentix Medical, Inc.
9.15.1 Overview
9.15.2 Financial Performance
9.15.3 Product Outlook
9.15.4 Key Development

10 Appendix
10.1 Related Reports